Zamora Leon Jesus purchased $135K of AUNA

Zamora Leon Jesus (President) purchased 32,000 shares of AUNA S.A. (AUNA) at an average of $4.21 ($4.20–$4.24, $0.13M total) across 2 trades over 2026-05-26 to 2026-05-27.

Original reporting
SEC EDGAR · Zamora Leon Jesus
Published May 28, 2026, 4:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 6, 2026, 8:40 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$AUNA
Bullish
medium confidence
Mentioned
$AUNA
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$AUNABullishLow
01

Why it matters

The newest fact is the open-market purchase details and post-transaction holdings, which may slightly influence sentiment but does not change operating outlook based on the provided text.

02

Market read

Traders may note the insider buy as a small positive sentiment datapoint, but there is no accompanying fundamental or regulatory catalyst in the text.

03

What to watch

The article does not state whether the purchase was motivated by valuation views, compensation timing, or other personal factors; also, the disclosed size may be small relative to total float.

Relevance 5/10Novelty 4/10Timing: filed 2026-05-28, covering buys on 2026-05-26 to 2026-05-27

Background

This is an SEC Form 4 insider transaction disclosure for AUNA S.A., reported by its President and director.

Company-level read

Ticker impact

$AUNABullishMedium confidence
Context

AUNA insider Form 4 shows President Zamora Leon Jesus bought 32,000 shares in open-market trades at about $4.21.

Expected impact

Likely limited near-term impact; any effect is more sentiment than fundamentals.

Evidence & confidence

Form 4 insider purchases can support bullish sentiment, but the article provides no guidance, earnings, deal, or regulatory development, and the transaction lacks a 10b5-1 plan.

Market effects

No sector-level signal; this is a single-company insider transaction.

None indicated.

None indicated.

Counterpoint

Insider buys can be routine liquidity or diversification rather than a strong signal, especially without context on prior trading patterns.

Key entities

  • AUNA S.A.

    Subject of the Form 4 insider transaction; President Zamora Leon Jesus reported an open-market purchase.

  • Zamora Leon Jesus

    President and officer/director who purchased 32,000 shares across two trades.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$AUNAMed

Auna S.A. (AUNA) Stock Falls on Q3 2026 Earnings

Auna S.A. (AUNA) reported Q3 2026 revenue of $384.7M, up 19.4% YoY, with net income falling 57.4% to $5.9M. Operating cash flow rose 38.9% to $77.6M. Insiders made 6 purchases and 1 sale in the past 6 months. Hedge funds showed mixed activity, with some increasing and others decreasing positions.

$AUNAMed

AUNA S.A. (AUNA): Financial results for Q3 2026

AUNA S.A. (AUNA) furnished an SEC Form 6-K — earnings release. Exhibit 99.1 Auna Announces 3Q26 Financial Results Auna reports 10% FX-Neutral Revenue Growth and Continued Strong Cash Generation in 3Q2026; Mexico Returns to Year-over-Year Adjusted EBITDA Growth; Profitability Pressured by Specific Headwinds in Colombia and Peru Leverage Impro

$AUNAHigh

Why is Auna stock dropping today?

Auna SAA ADR stock fell 9.2% to $4.91 after revising its 2026 profitability outlook, citing higher cancer diagnosis costs in Colombia. The company maintained its revenue growth target but saw a sell-off amid broader market declines. The stock dropped to a session low of $4.55, nearing its 52-week low of $4.09.

$AUNAMed

Auna (AUNA) Q2 2026 Earnings Call Transcript

Auna (AUNA) reported Q2 2026 results with 9% revenue growth driven by volume and higher complexity services. Adjusted EBITDA declined 9% due to margin pressures in Mexico and Colombia, and billing penalties in Peru. Mexico saw 7% surgery and 20% oncology volume growth, while Peru achieved 8% revenue growth. Colombia's adjusted EBITDA increased 18% sequentially. Leverage decreased to 3.6x, and cash increased 43% year-over-year.